Plain-English translation of NCT03810651 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This pilot study is testing pencil beam scanning proton therapy, a newer type of radiation treatment that aims to precisely target kidney tumors while sparing surrounding healthy organs. Unlike traditional radiation, this approach delivers radiation energy more selectively to the tumor area, potentially causing fewer side effects. The trial will track how well this treatment works and how safe it is for young patients who need radiation as part of their kidney cancer care.
Children and young adults treated for kidney tumors have excellent long-term survival, but the standard radiation therapy can cause harm to healthy organs nearby and lead to complications later in life. This trial exists to see whether the new treatment can be just as effective at fighting cancer while reducing these potential harms.
You likely qualify if…
You likely don't qualify if…
You would receive the new pencil beam scanning radiation therapy as your standard cancer treatment, delivered over several weeks at the hospital. Your medical team will monitor you closely during and after treatment using blood tests, physical exams, and quality-of-life questionnaires to track how you're doing and watch for any side effects. The study will compare how much radiation reaches your healthy organs using this new method versus the traditional approach.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Children's Hospital of Philadelphia
Enrollment target
~28 participants
Started
December 2017
Primary completion
October 2027
Age range
0 Years – 30 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christine Hill-Kayser, MD
Children's Hospital of Philadelphia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.